Hoffbrand's essential haematology / created by A. Victor Hoffbrand ; contributing authors, Pratima Chowdary, Graham Collins, Justin Loke.

Includes bibliographical references and index.

Haemopoiesis -- Erythropoiesis and general aspects of anaemia -- Hypochromic anaemias -- Iron overload -- Megaloblastic anaemias and other macrocytic anaemias -- Haemolytic anaemias -- Genetic disorders of haemoglobin -- The white cells, part 1 : granulocytes, monocytes and their benign disorders -- The white cells, part 2 : lymphocytes and their benign disorders -- The Spleen -- The aetiology and genetics of haematological neoplasia -- Management of haematological malignancy -- Acute myeloid leukaemia -- Chronic myeloid leukaemia -- Myeloproliferative neoplasms -- Myelodysplastic neoplasias -- Acute lymphoblastic leukaemia -- The chronic lymphocytic leukaemias -- Hodgkin Lymphoma -- Non-Hodgkin lymphomas 1: General aspects -- Non-Hodgkin lymphomas -- Multiple myeloma and related plasma cell neoplasms -- Amyloid -- Aplastic anaemia and bone marrow failure syndromes -- Haemopoietic stem cell transplantation -- Platelets, coagulation and normal haemostasis -- Bleeding disorders caused by platelet and vascular abnormalities -- Hereditary coagulation disorders -- Acquired coagulation disorders and thrombotic microangiopathies -- Thrombosis 1 : Pathogenesis and diagnosis -- Thrombosis 2 : Treatment -- Haematological changes in systemic diseases -- Blood transfusion -- Pregnancy and neonatal haematology.

"Advances in the understanding the pathogenesis of blood diseases and improvements in their treatment have continued apace in the five years since the 8th edition of HEH was published. Gene mutations are increasingly used to define and classify inherited and acquired haematological diseases, as a guide to therapy and to predict prognosis. Mutations underlying many rarer blood diseases have been identified, allowing appropriate panels of DNA probes to be established, facilitating the diagnosis of future cases. Many more drugs directed against specific sites in the cell signalling pathways have been approved"-- Provided by publisher.